期刊信息/Journal information
：西安交通大学
：季刊
：2950-2667
：pandp@mail.xjtu.edu.cn;ppeditor@xjtu.edu.cn
：712046
：陕西省西安市长安区高桥街道西安交通大学
Pharmacoeconomics and Policy/Journal 药物经济与政策（英文）
《药物经济与政策（英文）》（Pharmacoeconomics and Policy）（季刊），由西安交通大学主办。期刊聚焦国内外药物经济学、卫生技术评估、人工智能等颠覆性技术驱动的创新医疗技术和药械...展开全部>>
收录年份
Cost-effectiveness analysis of bevifibatide for patients with acute coronary syndrome undergoing percutaneous coronary intervention in China
Kaijie Yao;Yun Bao;Ying Chen;Yan Zhong;Mengxia Yan;Wen Li;Bin Wu;P.46-53
Clinical burden and health-related quality of life in Chinese patients with mucopolysaccharidosis type Ⅱ under 16 years
Zixuan Lyu;Min Li;Yaqun Wang;Pei Wang;Shengnan Duan;Huaxin Yu;Kexin Li;Jun Hu;Ni Yuan;P.38-45
Current clinical practice including treatment patterns and pathways in idiopathic pulmonary fibrosis patients in China:A real-world analysis
Han Bao;Yifei Jian;Cristina Penaloza‑Ramos;Madhu Kanakapura;Zhongyi Deng;Jianwei Xuan;Hui Zhao;P.27-37
Cost-effectiveness analysis of toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China
Yize Jia;Shuo Yang;Shan Zhao;Shuo Kang;P.19-26
Disease burden and productivity loss of T2DM in the Western Pacific region from 1990 to 2050:A modeling study using GBD 2021
Luyou Dong;Dachuang Zhou;Wenxi Tang;P.12-18
Cost-effectiveness of clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention:A systematic review
Saba Abidi;Shridhar Dwivedi;Vinod Sharma;Anoop Kumar;Sushama Talegaonkar;P.4-11
Comments on the 2025 Edition of China Guidelines for Pharmacoeconomic Evaluations
Jing Wu;Gordon G.Liu;P.1-3